Common Transcriptional Program of Liver Fibrosis in Mouse Genetic Models and Humans

Common Transcriptional Program of Liver Fibrosis in Mouse Genetic Models and Humans

Multifactorial metabolic diseases, such as non-alcoholic fatty liver disease, are a major burden to modern societies, and frequently present with no clearly defined molecular biomarkers. Herein we used system medicine approaches to decipher signatures of liver fibrosis in mouse models with malfuncti...

Full description

Bibliographic Details
Main Authors:	Kaja Blagotinšek Cokan, Žiga Urlep, Miha Moškon, Miha Mraz, Xiang Yi Kong, Winnie Eskild, Damjana Rozman, Peter Juvan, Tadeja Režen
Format:	Article
Language:	English
Published:	MDPI AG 2021-01-01
Series:	International Journal of Molecular Sciences
Subjects:	NAFLD NASH bile acid GEM fibrosis fatty acid
Online Access:	https://www.mdpi.com/1422-0067/22/2/832

Similar Items

LiverSex Computational Model: Sexual Aspects in Hepatic Metabolism and Abnormalities
by: Tanja Cvitanović Tomaš, et al.
Published: (2018-04-01)

The Presence and Severity of Nonalcoholic Steatohepatitis Is Associated with Specific Changes in Circulating Bile Acids
by: Aline Gottlieb, et al.
Published: (2018-05-01)

Guided extraction of genome-scale metabolic models for the integration and analysis of omics data
by: Andrew Walakira, et al.
Published: (2021-01-01)

Computational modelling of liver metabolism and its applications in research and the clinics
by: Tanja Cvitanović Tomaš, et al.
Published: (2018-06-01)

Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways
by: Yanyan Wang, et al.
Published: (2021-01-01)

An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials
by: Wei-Qiang Leow, et al.
Published: (2020-08-01)

NASH-related increases in plasma bile acid levels depend on insulin resistance
by: Guillaume Grzych, et al.
Published: (2021-04-01)

Comparison between NAFLD fibrosis score and retinoic acid serum level in NAFLD
by: Ahmed Samir Allam, et al.
Published: (2020-01-01)

Non-Invasive Diagnostic Test for Advanced Fibrosis in Adolescents With Non-Alcoholic Fatty Liver Disease
by: Antonella Mosca, et al.
Published: (2022-04-01)

Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD)
by: Francesco Vizzutti;, et al.
Published: (2009-04-01)

Chronic Disruption of the Late Cholesterol Synthesis Leads to Female-Prevalent Liver Cancer
by: Kaja Blagotinšek Cokan, et al.
Published: (2020-11-01)

Factores analíticos, antropométricos y dietéticos asociados al desarrollo de fibrosis en pacientes con enfermedad por hígado graso no alcohólico
by: Sara Gómez-de-la-Cuesta, et al.

Mechanism and Progress of Natural Products in the Treatment of NAFLD-Related Fibrosis
by: Jin-Zhong Li, et al.
Published: (2023-12-01)

Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease
by: Sachiyo Yoshio, et al.
Published: (2021-07-01)

Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
by: Jian Huang, et al.
Published: (2023-04-01)

Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression
by: Aline Gottlieb, et al.
Published: (2019-10-01)

Production, Exacerbating Effect, and EV-Mediated Transcription of Hepatic CCN2 in NASH: Implications for Diagnosis and Therapy of NASH Fibrosis
by: Xinlei Li, et al.
Published: (2023-08-01)

The Crosstalk between Gut Microbiota and Bile Acids Promotes the Development of Non-Alcoholic Fatty Liver Disease
by: Zhonglin Li, et al.
Published: (2023-08-01)

Type IV collagen as marker of fibrosis in nonalcoholic liver disease
by: Alvina
Published: (2010-08-01)

Type IV collagen as marker of fibrosis in nonalcoholic liver disease
by: Alvina Alvina
Published: (2016-02-01)

Evaluación de fibrosis en pacientes con enfermedad por hígado graso no alcohólico: adherencia a los algoritmos propuestos y barreras para cumplir con ellos
by: S. Marciano, et al.
Published: (2022-01-01)

Interleukin-13 (IL-13)—A Pleiotropic Cytokine Involved in Wound Healing and Fibrosis
by: Elke Roeb
Published: (2023-08-01)

High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients
by: Juan P. Arab, et al.
Published: (2016-09-01)

Bile Acids and Biliary Fibrosis
by: Sayed Obaidullah Aseem, et al.
Published: (2023-03-01)

A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology
by: Anita M. van den Hoek, et al.
Published: (2020-09-01)

Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan
by: Tran Thi Khanh Tuong, et al.
Published: (2020-03-01)

Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist
by: An-Na Moon, et al.
Published: (2024-04-01)

Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases
by: Rocío Gallego-Durán, et al.
Published: (2021-11-01)

Nonalcoholic Fatty Liver Disease Progresses into Severe NASH when Physiological Mechanisms of Tissue Homeostasis Collapse
by: Silvia Sookoian, et al.
Published: (2018-03-01)

Context-Specific Genome-Scale Metabolic Modelling and Its Application to the Analysis of COVID-19 Metabolic Signatures
by: Miha Moškon, et al.
Published: (2023-01-01)

Liver fibrosis prevalence and risk factors in patients with psoriasis: A systematic review and meta-analysis
by: Tanat Yongpisarn, et al.
Published: (2022-12-01)

Imaging biomarkers of NAFLD, NASH, and fibrosis
by: Veeral Ajmera, et al.
Published: (2021-08-01)

Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis
by: Abdulrahman Ismaiel, et al.
Published: (2021-07-01)

Enhancing Hepatic MBOAT7 Expression in Mice With Nonalcoholic Steatohepatitis
by: Martin C. Sharpe, et al.
Published: (2023-01-01)

Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease
by: Jingjing Jiao, et al.
Published: (2023-02-01)

New Insights into the Role of KLF10 in Tissue Fibrosis
by: Uzma Yaseen, et al.
Published: (2024-01-01)

A continuous-time Markov chain model of fibrosis progression in NAFLD and NASH
by: Lyndsey F. Meyer, et al.
Published: (2023-05-01)

Double Trouble: How Microbiome Dysbiosis and Mitochondrial Dysfunction Drive Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
by: Wesam Bahitham, et al.
Published: (2024-02-01)

Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation
by: José A. Inia, et al.
Published: (2023-04-01)

Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice
by: José A. Inia, et al.
Published: (2023-05-01)